Aurora kinase A inhibition: A mega-hit for myelofibrosis therapy?

Richard T. Piszczatowski, Ulrich Steidl

Research output: Contribution to journalArticle

Abstract

The positive but limited efficacy of JAK inhibitors has sparked the need for alternative therapeutic targets in the treatment of myelofibrosis. The discovery of novel targets, like Aurora Kinase A, may provide new avenues of single-agent and combinatorial therapy for myelofibrosis and restoration of normal bone marrow function.

Original languageEnglish (US)
Pages (from-to)4868-4870
Number of pages3
JournalClinical Cancer Research
Volume25
Issue number16
DOIs
StatePublished - Jan 1 2019

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this